Letter to the EditorEpidemiology and case-control study of Lassa fever outbreak in Nigeria from 2018 to 2019
Section snippets
Declaration of Competing Interest
The authors have declared that no conflicts of interest exist.
Funding
This work was partially supported by the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan and the Japan Society for the Promotion of Science (grant number, 16809810). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Acknowledgments
We thank all the staff of the domestic and international organizations who fought against this outbreak, including those at the various health care facilities, Lassa fever diagnostic laboratories, Nigeria Centre for Disease Control, World Health Organization, African Field Epidemiology Network, Public Health England, eHealth Africa, Pro Health International, University of Maryland Baltimore, US Centers for Disease Control and Prevention, Alliance for International Medical Action, Médecins Sans
References (10)
- et al.
A unified personal protective equipment ensemble for clinical response to possible high consequence infectious diseases: a consensus document on behalf of the HCID programme
J Infect
(2018) - et al.
Lassa fever: epidemiology, clinical features, and social consequences
BMJ Br Med J
(2003) - World Health Organization. Lassa fever fact sheet. Available athttp://origin.who.int/mediacentre/factsheets/fs179/en/....
- Centers for Disease Control and Prevention. Lassa Fever. Available athttp://www.cdc.gov/vhf/lassa/. Accessed May 13,...
- et al.
Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice
BMJ
(1995)
Cited by (9)
Lassa Virus Infection: a Summary for Clinicians
2022, International Journal of Infectious DiseasesCitation Excerpt :The true effectiveness of ribavirin as post-exposure prophylaxis has not been calculated, as the rate of secondary transmission of infection after exposure is unknown. When used for post-exposure prophylaxis, adverse events such as changes in mood, dizziness, fatigue, fever, headaches, nausea, and weakness, are common; therefore, considerations of risks versus benefits are important (Crowcroft et al., 2004; Hadi et al., 2010; Isa et al., 2016). Ribavirin should be administered with food as a proposed 10-day course consisting of a 35 mg/kg loading dose followed by 15 mg/kg 3 times daily (Bausch et al., 2010).
Lassa fever in Nigeria: Case fatality ratio, social consequences, and prevention
2023, Emerging Pandemics: Connections with Environment and Climate ChangeTransplacental transfer of Lassa IgG antibodies in pregnant women in Southern Nigeria: A prospective hospital-based cohort study
2023, PLoS Neglected Tropical DiseasesRecurring Outbreaks of Lassa Fever in Nigeria: Understanding the Root Causes and Strategies for the Future
2023, Sudan Journal of Medical SciencesGeographical drivers and climate-linked dynamics of Lassa fever in Nigeria
2021, Nature Communications
- 1
These authors contributed equally to this article.